The company is a spin-off of the National Institute of Molecular Genetics “Romeo and Enrica Invernizzi” (INGM).

The central point of Professor Beatrice Bodega’s discovery, co-founder of T-One Therapeutics, is attributing for the first time a crucial function in regulating the activation of T lymphocytes to certain sequences of human DNA (LINE1), sequences considered genetic waste for years.

Researchers at INGM instead discovered that these sequences are essential in inhibiting the functionality of T lymphocytes, immune system cells that are the primary pharmacological target for tumor immunotherapy (a therapy that has revolutionized the field of anti-tumor treatments in the last 10 years).